Revium Rx (RVRC) Common Equity (2024 - 2026)

Revium Rx has disclosed Common Equity across 3 years of filings, most recently posting $5.5 million for Q2 2026.

• In Q2 2026, Common Equity fell 70.21% year-over-year to $5.5 million; the TTM figure through Jun 2026 stood at $5.5 million (down 70.21% YoY), while the FY2025 annual figure was $6.9 million, down 65.08% from the prior year.
• Common Equity came in at $5.5 million for Q2 2026 at Revium Rx, down from $6.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $19.7 million in Q4 2024 to a low of $5.5 million in Q2 2026.
• Average Common Equity over 3 years is $12.7 million, with a median of $12.7 million recorded in 2025.
• Year-over-year, Common Equity plunged 65.08% in 2025 and plunged 70.21% in 2026.
• Over 3 years, Common Equity stood at $19.7 million in 2024, then sank by 65.08% to $6.9 million in 2025, then retreated by 19.79% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $5.5 million in Q2 2026, $6.9 million in Q4 2025, and $18.5 million in Q2 2025.